Novo Nordisk
Novo Nordisk cuts 650 roles around the world in R&D restructure
October 1, 2018Manufacturing and Production, Sales and Marketing China, Denmark, Novo Nordisk, UK, US, pharma
Novo Nordisk has announced a wave of jobs cuts as part of a global restructure of its $1 billion R&D …
Top Ten most popular articles on Pharmafile.com this week
September 21, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jobs, Novartis, Novo Nordisk, Senate, UCB, manufacturing, opioid crisis, top 10
Manufacturing took a hit this week as Novo Nordisk announced the loss of 400 jobs while Novartis made the move …
400 jobs to go as Novo Nordisk overhauls R&D operations
September 18, 2018Manufacturing and Production, Sales and Marketing Novo Nordisk, pharma
Novo Nordisk has revealed its intention to restructure its research & development operations “to accelerate the expansion and diversification of …
Pfizer, Novartis, MSD, Novo and GSK halt operations in wake of Hurricane Florence
September 14, 2018Medical Communications GSK, Hurricane Florence, MSD, Novartis, Novo Nordisk, Pfizer, pharma
As Hurricane Florence begins to breach the Southeast Coast, major pharma firms have announced they are enacting contingency plans, including …
Top Ten most popular articles on Pharmafile.com this week
September 14, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, FDA, NICE, Novo Nordisk, Spinraza, brexit, bristol myers squibb, top 10
With the Pharmafocus team having avoided hurricane Florence and finally arriving back in the UK just last night, after stopping …
Novo Nordisk stockpiles 16 weeks’ worth of insulin in preparation for hard Brexit
September 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Novo Nordisk, UK, brexit, insulin, pharma, stockpiles
Danish multinational Novo Nordisk has announced that they are increasing their stocks of insulin products to ensure that there are …
Novo Nordisk buys Bristol University biotech in £620m deal
August 22, 2018Research and Development Bristol, Novo Nordisk, Ziylo, diabetes
Novo Nordisk has bought a tiny biotech company spun out of Bristol University in a deal that could be worth …
Novo’s semaglutide hits the mark in Phase 3 type 2 diabetes study
August 21, 2018Manufacturing and Production, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes
Novo Nordisk has revealed new Phase 3a data on its glucagon-like peptide-1 (GLP-1) analogue oral semaglutide in the treatment of …
Novo Nordisk Pharmatech A/S enters a distribution agreement with Signet Chemical Corporation
August 3, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, pharma, signet chemical corporation
Novo Nordisk Pharmatech A/S enters a distribution agreement with Signet Chemical Corporation Pvt. Ltd. for cGMP Quaternary Ammonium Compounds for …
Novo’s oral semaglutide beats Victoza and Januvia in diabetes
June 21, 2018Research and Development Januvia, MSD, Novo Nordisk, Victoza, pharma, semaglutide
Novo Nordisk has released new data for its oral semaglutide diabetes therapy from two trials, showing that the GLP-1 analogue …
Kallyope and Novo Nordisk announce obesity and diabetes collaboration
June 20, 2018Research and Development Kallyope, Novo Nordisk, diabetes, obesity, pharma
Kallyope and Novo Nordisk have entered into a research collaboration and option agreement to discover novel peptide therapeutics for the …
Novo Nordisk delivers in much-anticipated oral semaglutide diabetes trial
February 23, 2018Medical Communications, Research and Development Novo Nordisk, diabetes, pharma, semaglutide, type 2 diabetes
Novo Nordisk has lifted the curtain on much-anticipated results data from the first of ten Phase 3 trials into the …
Novo’s Ozempic secures European approval in type 2 diabetes
February 12, 2018Sales and Marketing EC, EMA, Europe, Novo Nordisk, diabetes, pharma
Novo Nordisk has revealed that its drug Ozempic (semaglutide) has received approval from the European Commission (EC) as a monotherapy …
Novo Nordisk ups acquisition bid to €2.6 billion, Ablynx says no
January 8, 2018Sales and Marketing Ablynx, Novo Nordisk, acquisition, pharma
It has emerged that Novo Nordisk has extended a bid of €2.6 billion to buy Belgian biotech Ablynx. The new …
Novo Nordisk unveils hard-hitting data for two of its diabetes therapies
December 5, 2017Manufacturing and Production, Research and Development Novo Nordisk, Tresiba, Xultophy, diabetes, pharma
Novo Nordisk has lifted the curtain on new data from two of its therapies for diabetes, Xultophy (insulin degludec/liraglutide) and …
